For the Inventor, By the Inventor

Enter assignee name

Foster City, CA, United States of America

Terns Pharmaceuticals, Inc.

USPTO Granted Patents = 13

EPO Patents = 4

Forward Citations = 14

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

F Anthony Romero (11 out of 42 patents)

Christopher T Jones (9 out of 9 patents)

Corey Reeves (8 out of 8 patents)

4. Martijn Fenaux (7 out of 18 patents)

5. Randall Halcomb (4 out of 46 patents)

6. Yingzi Xu (4 out of 8 patents)

7. Thorsten A Kirschberg (4 out of 44 patents)

8. Gary W Luehr (3 out of 3 patents)

9. Kevin P Quinn (2 out of 2 patents)

10. Olivia D Teal (1 out of 1 patent)

11. Jeffrey R Jasper (1 out of 1 patent)

12. Shanghai Yu (0 patent)

13. Ben Li (0 patent)

14. Ben Li (0 patent)

15. Shanghai Yu (0 patent)

13 patents: Sort by Forward Citations

1. 12528791 - Thyroid hormone receptor beta agonist compounds (2026-01-20),

2. 12522596 - Compounds as GLP-1R agonists (2026-01-13),

3. 12486261 - Compounds as GLP-1R agonists (2025-12-02),

4. 12485118 - Combinations of GLP-1R and THRβ agonists and methods of use thereof (2025-12-02),

5. 12454524 - (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias (2025-10-28),

6. 12410163 - Compounds as GLP-IR agonists (2025-09-09),

7. 12398127 - Thyroid hormone receptor beta agonist compounds (2025-08-26),

8. 12378239 - Compounds as GLP-1R agonists (2025-08-05),

9. 12378238 - Compounds as GLP-1R agonists (2025-08-05),

10. 12378237 - Compounds as GLP-1R agonists (2025-08-05),

11. 12378236 - Compounds as GLP-1R agonists (2025-08-05),

12. 12240835 - Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity (2025-03-04),

13. 12024507 - Compounds as GLP-1R agonists (2024-07-02),

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and metabolic diseases. The company is dedicated to addressing unmet medical needs through its proprietary drug candidates, which target key pathways involved in liver health and metabolic function. Terns is committed to advancing its pipeline of novel therapeutics, leveraging its expertise in drug development and a strong scientific foundation. With a focus on collaboration and innovation, Terns aims to improve the lives of patients suffering from chronic liver diseases and related conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

13 Patents

#36 in Foster City, CA

#5,642 in California

#23,785 in US

#44,914 in the World

Foster City, CA, United States of America

Terns Pharmaceuticals, Inc.

Forward Citations = 14

15 inventors:

F Anthony Romero (11 out of 42 patents)

Christopher T Jones (9 out of 9 patents)

Corey Reeves (8 out of 8 patents)

4. Martijn Fenaux (7 out of 18 patents)

5. Randall Halcomb (4 out of 46 patents)

Please report any incorrect information to [email protected]

Loading…